Investigation of Nano-liposomal Doxorubicin penetration in glioblastoma tumor cells

Glioblastoma (GBM) is one of the most malignant types of cancer in humans. Despite advancements in cancer treatments such as surgery, radiotherapy and chemotherapy, high-grade glioma is still extremely fetal. Research on treating cancerous tumors using liposomal nanomedicines has made significant progress in recent years, and various medicines have also been commercialized. Increasing research on the delivery of Doxorubicin (DOX) using nanoparticles, especially nanoliposomes, has been conducted due to the importance of drug delivery in improving DOX performance. liposomal doxorubicin has been commercialized, such as Doxil®, which is FDA approved since ۱۹۹۵, Caelyx®, DOXOrubicin and SinaDoxosome. In this study, we investigated SinaDoxosome penetration into U-۸۷ MG cells utilizing Epi-fluorescent microscopy. The morphology of cells was investigated using Bright-field microscopy. Cells were treated with ۰.۵ μg/ml, ۵ μg/ml and ۵۰ μg/ml drug concentrations for ۴۸ hours. It was shown that the drug penetrates and localizes in the cell nucleus. With the increase in drug concentration, the cell population decreases significantly, and the morphology of the cells changes.

Keywords:

Glioblastoma , Drug delivery , Nanoliposomal Doxorubicin , drug penetration , Epi-fluorescent Microscopy , Bright-field Microscopy.